US20170340662A1 - Weight reducing composition - Google Patents
Weight reducing composition Download PDFInfo
- Publication number
- US20170340662A1 US20170340662A1 US15/678,264 US201715678264A US2017340662A1 US 20170340662 A1 US20170340662 A1 US 20170340662A1 US 201715678264 A US201715678264 A US 201715678264A US 2017340662 A1 US2017340662 A1 US 2017340662A1
- Authority
- US
- United States
- Prior art keywords
- water
- sodium
- magnesium
- weight
- experiment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 229910001868 water Inorganic materials 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000011734 sodium Substances 0.000 claims abstract description 31
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 28
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 28
- 239000011777 magnesium Substances 0.000 claims abstract description 27
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 24
- 235000005911 diet Nutrition 0.000 abstract description 13
- 230000009467 reduction Effects 0.000 abstract description 12
- 235000006694 eating habits Nutrition 0.000 abstract description 10
- 235000020188 drinking water Nutrition 0.000 abstract description 7
- 239000003651 drinking water Substances 0.000 abstract description 7
- 230000000378 dietary effect Effects 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 235000014214 soft drink Nutrition 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 21
- 206010033307 Overweight Diseases 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 230000037213 diet Effects 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 230000002048 spasmolytic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000020682 bottled natural mineral water Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241001116389 Aloe Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 229910003641 H2SiO3 Inorganic materials 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical compound [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to dietetic nutrition and can be used for reducing weight (weight loss).
- the overweight problem is among the most pressing issues of the present day dietetics. More than 20% of the population suffers from various degrees of obesity, whereas for adult population aged over 40 years the overweight is a problem for more than 40%.
- Sibutramine, leptin and cholecystokinin are among the known drugs that influence the hunger centre in brain and lower the appetite. These drugs must be used under medical supervision due to high risk of such side effects as allergies, hypertension, tachycardia, etc.
- Drugs that prevent absorption of fats in the intestine are also wide known and include biguanide derivatives, orlistat [see Encyclopedia of Drugs, edition 7, 2000, p. 475] and various herbal infusions. Orlistat inhibits intestinal lipase, thus blocking the breaking down of triglycerides in the intestine and reducing the absorption of free fatty acids and monoglycerides. Use of such drugs is almost always accompanied by diarrhoea, urgent bowel movements and fecal incontinence, resulting in significant inconveniences for the patients.
- Water from various natural sources contains mineral salts that define its taste as well as the therapeutic properties. Unlike therapeutic water, table water usually has low mineral content. Purified and then remineralized water is also popular. As a rule, such water falls into the table water category and is not intended for use in treatment or prevention of overweight.
- a known composition comprises (mg/I):
- Bicarbonate HCO 3 1000-1200 Sulfate SO 4 900-1700 Chloride Cl 300-500 Calcium Ca 300-400 Magnesium Mg ⁇ 100 Sodium + Potassium (Na + K) 700-1200 Silicic acid H 2 SiO 3 30-90 Mineral content 3.2-5.8 g/l
- Bicarbonate HCO 3 3900-4900 Sulfate SO 4 ⁇ 100 Chloride Cl 600-800 Calcium Ca ⁇ 100 Magnesium Mg ⁇ 75 Sodium + Potassium (Na + K) 1700-2700
- This mineral water has the same disadvantages as Novoterskaya Tselebnaya water.
- the content of the “therapeutic natural table water Rosinka”, TU-9185-001-05126800-97, is the closest one to the inventive engineering solution and comprises (mg/l):
- Bicarbonate HCO 3 100-200 Sulfate SO 4 ⁇ 30 Chloride Cl ⁇ 80 Calcium Ca ⁇ 20 Magnesium Mg ⁇ 25 Sodium + Potassium (Na + K) ⁇ 30 Mineral content 0.3 g/l
- the “therapeutic natural table water Rosinka” has low efficiency in overweight treatment.
- a weight reducing composition comprising cations of sodium, magnesium and water, wherein said components are included according to the following ratio:
- the participants of the experiment 10 volunteers aged 20-39 yrs—received the weight reducing composition comprising 0.01 mg/l of sodium and 25 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m 2 . Results of the experiment are shown in Table 2.
- the participants of the experiment 8 volunteers aged 20-39 yrs—received the weight reducing composition comprising 5.0 mg/l of sodium and 50 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 241.9.kg/m 2 . Results of the experiment are shown in Table 3.
- the participants of the experiment 10 volunteers aged 20-39 yrs—received the weight reducing composition comprising 10 mg/l of sodium and 150 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m 2 . Results of the experiment are shown in Table 4.
- the participants of the experiment 9 volunteers aged 20-39 yrs—received the weight reducing composition comprising 25 mg/l of sodium and 50 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m 2 . Results of the experiment are shown in Table 5.
- the participants of the experiment 9 volunteers aged 20-39 yrs—received the weight reducing composition comprising 1 mg/l of sodium and 10 mg/l of magnesium, the rest being water, at room temperature.
- the participants of the experiment 10 volunteers aged 20-39 yrs—received the “therapeutic natural table water Rosinka”, comprising less than 30 mg/l of sodium+potassium and less than 30 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m 2 . Results of the experiment are shown in Table 7.
- the participants of the experiment 10 volunteers aged 20-39 yrs—received the “natural mineral water Essentuki No. 4”, comprising 1700-2700 mg/l of sodium+potassium and less than 75 mg/l of magnesium, the rest being water, at room temperature.
- the participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 1.50 ml.
- Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m 2 ), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m 2 . Results of the experiment are shown in Table 8.
- inventive composition provides a twofold or even threefold increase in efficiency in comparison with the known compositions (Rosinka, Essentuki No. 4, Novoterskaya Tselebnaya) that are recommended as weight-reducing treatment for overweight people.
- Water-soluble vitamins can be added to the inventive composition, for example, ascorbic acid or B vitamins; also, one may add extracts or infusions of green tea, aloe, garcinia, gentiana, corn silk, turmeric, grapefruit, citric acid, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The invention relates to dietetic nutrition and can be used for reducing weight (weight loss).
- The overweight problem is among the most pressing issues of the present day dietetics. More than 20% of the population suffers from various degrees of obesity, whereas for adult population aged over 40 years the overweight is a problem for more than 40%.
- Today most treatments for overweight people that do not involve consultations with medical specialists consist mainly in modifying the diet and increasing physical exercise. The low energy diet (1200-1300 calories per day) is considered to be the most effective one, providing reduction of body weight by 6-7 kg within 6 months; however, the quantitative and qualitative restrictions on the food, as well as the need for certain changes in the eating habits and the daily routine, make the utilization of this technique rather difficult. Most patients that follow diets for a long time eventually go back to their usual eating habits, whereupon they gain back all of the lost weight.
- Sibutramine, leptin and cholecystokinin are among the known drugs that influence the hunger centre in brain and lower the appetite. These drugs must be used under medical supervision due to high risk of such side effects as allergies, hypertension, tachycardia, etc.
- Drugs that prevent absorption of fats in the intestine are also wide known and include biguanide derivatives, orlistat [see Encyclopedia of Drugs, edition 7, 2000, p. 475] and various herbal infusions. Orlistat inhibits intestinal lipase, thus blocking the breaking down of triglycerides in the intestine and reducing the absorption of free fatty acids and monoglycerides. Use of such drugs is almost always accompanied by diarrhoea, urgent bowel movements and fecal incontinence, resulting in significant inconveniences for the patients.
- It is a known fact that everyday intake of water is essential for humans. An adult individual must drink 2.0-2.5 litres of water every day. Water plays an important part in physiological processes of maintaining and/or changing the body mass. For example, fat is known to break down only in the presence of water. On the other hand, retention of water in the organism not only results in increased body mass and edemas, but can also increase the formation of fat deposits.
- Due to the important hygienic role of water, its quality is rigorously standardized and controlled. Different countries set their own principal hygienic standards for drinking water, which are based on similar values (see Table 1).
- Water from various natural sources contains mineral salts that define its taste as well as the therapeutic properties. Unlike therapeutic water, table water usually has low mineral content. Purified and then remineralized water is also popular. As a rule, such water falls into the table water category and is not intended for use in treatment or prevention of overweight.
- A known composition comprises (mg/I):
-
Bicarbonate HCO3 1000-1200 Sulfate SO4 900-1700 Chloride Cl 300-500 Calcium Ca 300-400 Magnesium Mg <100 Sodium + Potassium (Na + K) 700-1200 Silicic acid H2SiO3 30-90 Mineral content 3.2-5.8 g/l - see “therapeutic mineral table water Novoterskaya Tselebnaya”, TU9185-003-36800549-02. This water is recommended, in particular, for obese people. However, a very high content of sodium and undefined minimal amount of magnesium make this composition inefficient in treating the overweight problem; the water does not have any noticeable spasmolytic effect that would suppress hunger and increase the peristalsis and lipolysis. Hunger spasms play an important part in creating the sense of hunger, because they are perceived by the individual as the demand for food.
- Another known water, “natural mineral water Essentuki No. 4”, TU 9185-001-50243825-03, recommended for reducing the overweight, problem, comprises (mg/l):
-
Bicarbonate HCO3 3900-4900 Sulfate SO4 <100 Chloride Cl 600-800 Calcium Ca <100 Magnesium Mg <75 Sodium + Potassium (Na + K) 1700-2700 - This mineral water has the same disadvantages as Novoterskaya Tselebnaya water. The content of the “therapeutic natural table water Rosinka”, TU-9185-001-05126800-97, is the closest one to the inventive engineering solution and comprises (mg/l):
-
Bicarbonate HCO3 100-200 Sulfate SO4 <30 Chloride Cl <80 Calcium Ca <20 Magnesium Mg <25 Sodium + Potassium (Na + K) <30 Mineral content 0.3 g/l - The applicant performed analysis of the content of sodium and magnesium in 12 samples (12 bottles of Rosinka that were purchased in different sales points in St. Petersburg and Moscow). The results showed that the content of sodium in the samples varied from 24 to 35 mg/l, while the content of magnesium varied from 16 to 20 mg/l. However, as it was noted above, increased content of sodium causes retention of water in the organism; also this composition does not provide a noticeable spasmolytic effect.
- Due to the abovementioned disadvantages, the “therapeutic natural table water Rosinka” has low efficiency in overweight treatment.
- It is an object of the present invention to provide a weight 25 reducing composition that would efficiently aid in reduction of extra weight due to its ratio of ingredients.
- According to the invention there is provided a weight reducing composition comprising cations of sodium, magnesium and water, wherein said components are included according to the following ratio:
-
Na+ 0.01-10 mg/l Mg++ 25-150 mg/l H2O the rest - Anions are not so very important.
- The applicant has not found any sources of information containing data on engineering solutions identical to the present invention. In applicant's opinion, this enables to conclude that the invention conforms to the criterion “Novelty” (N).
- While analyzing the inventive engineering solution for conformance to the criterion “Inventive Step”, the applicant discovered a novel effect that had not been previously mentioned in any other sources, namely that magnesium has a pronounced spasmolytic effect on the stomach only under low concentrations of sodium, wherein the concentration of magnesium should be at least 2.5 mg/l; the intake of water causes irritation of mechanoreceptors of the stomach wall and secretion of cholecystokinin by I-cells of the duodenum, with subsequent transfer of impulses to the hunger center in hypothalamus and to the limbic system in the brain; this results in reduced secretion of gastric and intestinal juices, reduced absorption of nutrients, decreased feeling of hunger, increased peristalsis, intensified lipolysis; for this, the concentration of sodium must not exceed 10 mg/l (sodium concentrations below 0.01 mg/l are technically difficult to achieve). When the concentration of sodium exceeds 10 mg/l, the spasmolytic effect is not pronounced, even with magnesium concentrations above 25 mg/l. The effect is also absent for sodium concentrations below 10 mg/l if the concentration of magnesium is below 25 mg/l.
- Therefore, a pronounced spasmolytic effect can be obtained only when concentration of sodium is not higher than 10 mg/l and the concentration of magnesium is between 25 and 150 mg/l (magnesium content above 150 mg/l is not recommended due to purgative side effects.)
- The applicant has not found any sources of information containing data on the influence of the inventive novel features on the technical result produced through realization of said features. In applicant's opinion, this enables to conclude that the present engineering solution conforms to the criterion “Inventive Step” (IS).
- The invention is further explained, by way of example, without reference to any drawings.
- Utilization of the inventive composition is further illustrated by means of the following examples.
- The participants of the experiment—10 volunteers aged 20-39 yrs—received the weight reducing composition comprising 0.01 mg/l of sodium and 25 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 2.
- The participants of the experiment—8 volunteers aged 20-39 yrs—received the weight reducing composition comprising 5.0 mg/l of sodium and 50 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 241.9.kg/m2. Results of the experiment are shown in Table 3.
- The participants of the experiment—10 volunteers aged 20-39 yrs—received the weight reducing composition comprising 10 mg/l of sodium and 150 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 4.
- The participants of the experiment—9 volunteers aged 20-39 yrs—received the weight reducing composition comprising 25 mg/l of sodium and 50 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 5.
- This example shows that there were no statistically significant reduction of body weight (at least 1 kg after 30 days), even though the water contained sufficient amount of magnesium—the reason for this was high concentration of sodium.
- The participants of the experiment—9 volunteers aged 20-39 yrs—received the weight reducing composition comprising 1 mg/l of sodium and 10 mg/l of magnesium, the rest being water, at room temperature.
- The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 6.
- This example shows that even very low concentrations of sodium, when combined with insufficient concentration of magnesium, do not provide a significant reduction of body weight.
- The participants of the experiment—10 volunteers aged 20-39 yrs—received the “therapeutic natural table water Rosinka”, comprising less than 30 mg/l of sodium+potassium and less than 30 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 150 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 7.
- The participants of the experiment—10 volunteers aged 20-39 yrs—received the “natural mineral water Essentuki No. 4”, comprising 1700-2700 mg/l of sodium+potassium and less than 75 mg/l of magnesium, the rest being water, at room temperature. The participants drank this water during 30 days, twice a day, 5-10 minutes before the meal (before dinner and supper), in the amount of 1.50 ml. Their eating habits, diet, daily routine and physical exercise level remained the same as before the experiment. All participants were overweight according to the Body Mass Index (27.0-35.6 kg/m2), which is calculated by dividing body weight in kilograms by the square of the individual's height in meters. For individuals with normal weight this parameter ranges from 18.5 to 24.9 kg/m2. Results of the experiment are shown in Table 8.
- The abovementioned examples show that the inventive composition provides a twofold or even threefold increase in efficiency in comparison with the known compositions (Rosinka, Essentuki No. 4, Novoterskaya Tselebnaya) that are recommended as weight-reducing treatment for overweight people.
- Water-soluble vitamins can be added to the inventive composition, for example, ascorbic acid or B vitamins; also, one may add extracts or infusions of green tea, aloe, garcinia, gentiana, corn silk, turmeric, grapefruit, citric acid, etc.
- The realization of the invention is done by means of common 25 materials and factory equipment. In applicant's opinion, this enables to conclude that the invention conforms to the criterion “Industrial Applicability” (IA).
-
-
TABLE 1 RF Parameter Unit WHO* USEPA** EU*** SanPiN**** PH pH units 6.5-8.5 6.5-8.5 6-9 Total mineral mg/l <1000 <500 <1500 <1000 content Total hardness mmol/l <1.2 <7.0 *World Health Organization, Guidelines for Drinking-Water Quality, 1984 (revised and updated in 1992). **U.S. Environment Protection Agency, National Primary Drinking Water Regulations. ***Directive of the European Community (EC) regarding the quality of water intended for human consumption (80/778/EC) was approved by the European Council on 15 Jul. 1980. ****Sanitary Regulations and Standards of Russian Federation (SanPiN); (SanPiN 2.1.4.559-96) “Drinking water. Hygienic requirements to the quality of water in centralized systems of drinking water supply. Quality control” were approved by Resolution of Goskomsanepidnadzor RF (State Committee on Sanitary and Epidemiology Surveillance) of 24 Oct. 1996 and put into effect on 1 Jul. 1997. -
-
TABLE 2 Reduction of body weight among the Content of the participants (in kg) composition after 30 days Sodium-0.01 mg/l. 1.30 +/− 0.2 magnesium-25 mg/l, water-the rest. -
-
TABLE 3 Reduction of body weight among the Content of the participants (in kg) composition after 30 days Sodium-5.0 mg/l, 1.70 +/− 0.25 magnesium-50 mg/l, water-the rest. -
-
TABLE 4 Reduction of body weight among the Content of the participants (in kg) composition after 30 days Sodium-10 mg/l, 1.40 +/− 0.3 magnesium-150 mg/l, water-the rest. -
-
TABLE 5 Reduction of body weight among the Content of the participants (in kg) composition after 30 days Sodium-25 mg/l, 0.5 +/− 0.1 magnesium-50 mg/l, water-the rest. -
-
TABLE 6 Reduction of body weight among the Content of the participants (in kg) composition after 30 days Sodium-1 mg/l, 0.4 +/− 0.2 magnesium-10 mg/l, water-the rest. -
-
TABLE 7 Reduction of body Content of the weight among the “therapeutic natural participants (in kg) table water Rosinka” after 30 days Sodium + potassium-less than 30 mg/l, 0.55 +/− 0.15 magnesium-less than 30 mg/l, water-the rest. -
-
TABLE 8 Reduction of body Content of the weight among the “natural mineral water participants (in kg) Essentuki No. 4” after 30 days Sodium + potassium-1700-2700 mg/l, 0.50 +/− 0.3 magnesium-less than 75 mg/l, water-the rest.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/678,264 US20170340662A1 (en) | 2006-09-26 | 2017-08-16 | Weight reducing composition |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/443,043 US9205072B2 (en) | 2006-09-26 | 2006-09-26 | Weight reducing composition |
| PCT/RU2006/000501 WO2008039094A1 (en) | 2006-09-26 | 2006-09-26 | Weight reducing composition |
| US14/957,802 US9757413B2 (en) | 2006-09-26 | 2015-12-03 | Weight reducing composition |
| US15/678,264 US20170340662A1 (en) | 2006-09-26 | 2017-08-16 | Weight reducing composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/957,802 Continuation US9757413B2 (en) | 2006-09-26 | 2015-12-03 | Weight reducing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20170340662A1 true US20170340662A1 (en) | 2017-11-30 |
Family
ID=39230420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/443,043 Active 2027-05-10 US9205072B2 (en) | 2006-09-26 | 2006-09-26 | Weight reducing composition |
| US14/957,802 Active US9757413B2 (en) | 2006-09-26 | 2015-12-03 | Weight reducing composition |
| US15/678,264 Abandoned US20170340662A1 (en) | 2006-09-26 | 2017-08-16 | Weight reducing composition |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/443,043 Active 2027-05-10 US9205072B2 (en) | 2006-09-26 | 2006-09-26 | Weight reducing composition |
| US14/957,802 Active US9757413B2 (en) | 2006-09-26 | 2015-12-03 | Weight reducing composition |
Country Status (2)
| Country | Link |
|---|---|
| US (3) | US9205072B2 (en) |
| WO (1) | WO2008039094A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030021875A1 (en) * | 2000-08-24 | 2003-01-30 | Blank Arthur G. | Proficiency beverage |
| JP2005320278A (en) * | 2004-05-07 | 2005-11-17 | Suntory Ltd | Composition having autonomic nerve-adjusting activity and use of the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2137405C1 (en) * | 1998-12-17 | 1999-09-20 | Общество с ограниченной ответственностью "Аква Вита" | Alcohol-free beverage |
| RU2192153C2 (en) | 1999-11-19 | 2002-11-10 | Закрытое акционерное общество "Альфа" | Method of processing mineral water |
| US6649176B1 (en) * | 2000-06-29 | 2003-11-18 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing mineral water |
| KZ13953A (en) * | 2001-12-04 | 2004-02-16 | ||
| RU2221462C1 (en) | 2002-08-09 | 2004-01-20 | Кубанский государственный аграрный университет | Method for producing of beverage on citrus juice base |
| US20050106273A1 (en) * | 2003-10-14 | 2005-05-19 | Gholam Peyman | Appetite suppressant |
| CN1291665C (en) | 2004-06-21 | 2006-12-27 | 杭州娃哈哈集团有限公司 | Fat-reducing health beverage |
-
2006
- 2006-09-26 WO PCT/RU2006/000501 patent/WO2008039094A1/en not_active Ceased
- 2006-09-26 US US12/443,043 patent/US9205072B2/en active Active
-
2015
- 2015-12-03 US US14/957,802 patent/US9757413B2/en active Active
-
2017
- 2017-08-16 US US15/678,264 patent/US20170340662A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030021875A1 (en) * | 2000-08-24 | 2003-01-30 | Blank Arthur G. | Proficiency beverage |
| JP2005320278A (en) * | 2004-05-07 | 2005-11-17 | Suntory Ltd | Composition having autonomic nerve-adjusting activity and use of the same |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160082041A1 (en) | 2016-03-24 |
| US9205072B2 (en) | 2015-12-08 |
| US9757413B2 (en) | 2017-09-12 |
| US20100092580A1 (en) | 2010-04-15 |
| WO2008039094A1 (en) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2559755C (en) | Dietary supplement and method for treating digestive system-related disorders | |
| Walker et al. | Pica | |
| JP2010162040A (en) | Dietary supplement food and method of treating digestive system-related trouble | |
| Flaws | The tao of healthy eating: dietary wisdom according to traditional Chinese medicine | |
| US9757413B2 (en) | Weight reducing composition | |
| Subha | Medicinal properties of lime and its traditional food value | |
| Ruxton | Health aspects of caffeine: benefits and risks | |
| Baride et al. | Benefits of warm water | |
| RU2289287C1 (en) | Composition for weight loss | |
| JPH08140625A (en) | Nutrient-replenishing food | |
| CN108294138A (en) | A kind of beverage that can be refreshed the mind but also relieve fatigue | |
| CN101218977B (en) | Functional foods of pepper | |
| RU2070050C1 (en) | Agent for stimulation of motor-evacuator intestine function in children | |
| JP2000157207A (en) | Functional food | |
| WO2005107495A1 (en) | Mixed fruit concentrates against constipation and mehtod for preparation thereof | |
| Madden | Nurtitional benefits of drinks | |
| KR20040024008A (en) | Health food composition for improving constipation | |
| Bragg | Water, the shocking truth | |
| Shirah | The value of Mountain Sidr Honey in treating and controlling chronic constipation: A Prospective comparative study between Ziziphus honey and Lactulose in 1000 Saudi Arabian patients | |
| Sharama | Improve your health with Apple, Guava, Mango | |
| Arya | Food is your Medicine | |
| Kishimoto et al. | Relationship between health behavior and lifestyles/health status among Japanese adults | |
| CN105558733A (en) | Preparing formula for roselle amino acid plant beverage | |
| Fines | FIGHT THE FLU-8 BEST Natural Remedies | |
| JP2003079340A (en) | Health food for physical constitution improvement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |